ALSO NOTED: Genmab gets milestone payment from Roche; Mylan appoints CEO; and much more...

> Roche has filed a Clinical Trial Application for a Genmab antibody developed under the companies' collaboration. The CTA triggers a milestone payment for Genmab, the amount of which is undisclosed. Release

> Mylan has appointed Heather Bresch as CEO. Release

> San Diego-based medical device maker Vital Therapies has raised $28.1 million Series C financing. The new capital will support continued developed of ELAD, a human cell-based artificial liver. Release

> Here's a strategy for penetrating the market when state healthcare won't yet pay for your drug: Cut the price. Roche is doing just that with Tarceva, its lung cancer treatment. Report

> The FDA found "significant violations" of manufacturing rules at a French plant that produces Genzyme's Thymoglobulin drug for kidney transplants. Report

And Finally... Nigeria v. Pfizer in the matter of a meningitis vaccine trial went back to court today, with a judge allowing the authorities there to summon Pfizer and nine company officials to the country to defend themselves. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.